{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:59:51Z","timestamp":1793145591570,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"DOI":"10.1007\/s11926-025-01209-5","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:19:04Z","timestamp":1769851144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging Therapeutics in Rheumatoid Arthritis"],"prefix":"10.1007","volume":"28","author":[{"given":"Daniel J.","family":"Carlson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"3","key":"1209_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2669","volume":"11","author":"SE Gabriel","year":"2009","unstructured":"Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. https:\/\/doi.org\/10.1186\/ar2669.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1209_CR2","first-page":"S596","volume":"66","author":"D Sikes","year":"2014","unstructured":"Sikes D, Crump G, Thomas K, et al. Population management of rheumatoid arthritis (RA) in rheumatology practices: A quality improvement project. Arthritis Rheumatol: Abstract Supplement. 2014;66(11):S596.","journal-title":"Arthritis Rheumatol: Abstract Supplement"},{"issue":"1","key":"1209_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-2233","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update [published correction appears in ann rheum Dis. 2023;82(3):e76. Doi: 10.1136\/ard-2022-223356corr1]. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-2233.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1209_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10416","key":"1209_CR5","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8.","journal-title":"Lancet"},{"issue":"10","key":"1209_CR6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","volume":"77","author":"L Kearsley-Fleet","year":"2018","unstructured":"Kearsley-Fleet L, Davies R, De Cock D, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(10):1405\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213378.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1209_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","volume":"49","author":"M B\u00e9c\u00e8de","year":"2019","unstructured":"B\u00e9c\u00e8de M, Alasti F, Gessl I, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019;49(2):211\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.004.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1209_CR8","first-page":"1135","volume":"57","author":"MJH de Hair","year":"2018","unstructured":"de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57(7):1135\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1209_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ard-2024-226772","volume":"84","author":"KF Baker","year":"2025","unstructured":"Baker KF, Spierings J, Brom M, et al. Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration. Ann Rheum Dis. 2025;84(2):153\u20137. https:\/\/doi.org\/10.1136\/ard-2024-226772.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1209_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","volume":"56","author":"V Reddy","year":"2017","unstructured":"Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017;56(7):1227\u201337. https:\/\/doi.org\/10.1093\/rheumatology\/kex067.","journal-title":"Rheumatology (Oxford)"},{"key":"1209_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102561","volume":"94","author":"Yi Yin","year":"2025","unstructured":"Yin Yi, et al. Can we cure rheumatoid arthritis? Curr Opin Immunol. 2025;94:102561. https:\/\/doi.org\/10.1016\/j.coi.2025.102561.","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"1209_CR12","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","volume":"55","author":"S Alivernini","year":"2022","unstructured":"Alivernini S, Firestein GS, McInnes IB. The pathogenesis of rheumatoid arthritis. Immunity. 2022;55(12):2255\u201370. https:\/\/doi.org\/10.1016\/j.immuni.2022.11.009.","journal-title":"Immunity"},{"issue":"6","key":"1209_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529\u201342. https:\/\/doi.org\/10.1056\/NEJMra2103726.","journal-title":"N Engl J Med"},{"key":"1209_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/art.43105","author":"CM Weyand","year":"2025","unstructured":"Weyand CM, Goronzy JJ. Immune aging in rheumatoid arthritis. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43105.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1209_CR15","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"G Lliso-Ribera","year":"2019","unstructured":"Lliso-Ribera G, Humby F, Lewis M, et al. Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann Rheum Dis. 2019;78(12):1642\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215751.","journal-title":"Ann Rheum Dis"},{"issue":"7987","key":"1209_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","volume":"623","author":"F Zhang","year":"2023","unstructured":"Zhang F, Jonsson AH, Nathan A, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature. 2023;623(7987):616\u201324. https:\/\/doi.org\/10.1038\/s41586-023-06708-y.","journal-title":"Nature"},{"issue":"11","key":"1209_CR17","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","volume":"5","author":"Felice Rivellese","year":"2023","unstructured":"Rivellese Felice, et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. The Lancet Rheumatology. 2023;5(11):e648\u201359. https:\/\/doi.org\/10.1016\/S2665-9913(23)00241-2.","journal-title":"The Lancet. Rheumatology"},{"issue":"9","key":"1209_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-021-01822-2","volume":"17","author":"JD Murillo-Saich","year":"2021","unstructured":"Murillo-Saich JD, Diaz-Torne C, Ortiz MA, et al. Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study. Metabolomics. 2021;17(9):74. https:\/\/doi.org\/10.1007\/s11306-021-01822-2.","journal-title":"Metabolomics"},{"key":"1209_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1461756","volume":"15","author":"Peng Han","year":"2024","unstructured":"Han Peng, et al. Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective. Front Immunol. 2024;15:1461756. https:\/\/doi.org\/10.3389\/fimmu.2024.1461756.","journal-title":"Front Immunol"},{"key":"1209_CR20","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha Inhibition. New Engl J Med Vol. 2005;353:1114\u201323. https:\/\/doi.org\/10.1056\/NEJMoa050524.","journal-title":"New Engl J Med Vol"},{"issue":"3","key":"1209_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1209_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/PPO.0000000000000060","volume":"20","author":"S Yao","year":"2014","unstructured":"Yao S, Chen L. PD-1 as an immune modulatory receptor. Cancer J. 2014;20(4):262\u20134. https:\/\/doi.org\/10.1097\/PPO.0000000000000060.","journal-title":"Cancer J"},{"key":"1209_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103339","volume":"149","author":"Y Feng","year":"2024","unstructured":"Feng Y, Deyanat-Yazdi G, Newburn K, et al. <article-title update=\"added\">PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation \u2013 therapeutic implications for autoimmunity. J Autoimmun. 2024;149:103339. https:\/\/doi.org\/10.1016\/j.jaut.2024.103339.","journal-title":"J Autoimmun"},{"issue":"1","key":"1209_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/imr.13242","volume":"318","author":"G Reynolds","year":"2023","unstructured":"Reynolds G. Rheumatic complications of checkpoint inhibitors: lessons from autoimmunity. Immunol Rev. 2023;318(1):51\u201360. https:\/\/doi.org\/10.1111\/imr.13242.","journal-title":"Immunol Rev"},{"issue":"20","key":"1209_CR25","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","volume":"388","author":"J Tuttle","year":"2023","unstructured":"Tuttle J, Drescher E, Sim\u00f3n-Campos JA, et al. A phase 2 trial of Peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;388(20):1853\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2209856.","journal-title":"N Engl J Med"},{"key":"1209_CR26","unstructured":"Anaptys announces rosnilimab. Achieved positive results in RA phase 2b trial and highest ever reported CDAI LDA response over 6 months [news release]. AnaptysBio Inc.; 2025; 12."},{"key":"1209_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X251385857","author":"ITC Ling","year":"2025","unstructured":"Ling ITC, Marciniak SJ, Clarke SH, et al. Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study. Ther Adv Musculoskelet Dis. 2025. https:\/\/doi.org\/10.1177\/1759720X251385857.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"1209_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMc2307020","volume":"389","author":"D Nepal","year":"2023","unstructured":"Nepal D, Putman M. Phase 2 trial of Peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;389(4):378\u20139. https:\/\/doi.org\/10.1056\/NEJMc2307020.","journal-title":"N Engl J Med"},{"issue":"11","key":"1209_CR29","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.4049\/jimmunol.1601988","volume":"198","author":"Y Guo","year":"2017","unstructured":"Guo Y, Walsh AM, Fearon U, Smith MD, Wechalekar MD, Yin X, et al. CD40L-dependent pathway is active at various stages of rheumatoid arthritis disease progression. J Immunol. 2017;198(11):4490\u2013501. https:\/\/doi.org\/10.4049\/jimmunol.1601988.","journal-title":"J Immunol"},{"issue":"2","key":"1209_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/08916930109001958","volume":"34","author":"MF Liu","year":"2001","unstructured":"Liu MF, Chao SC, Wang CR, Lei HY. Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity. 2001;34(2):107\u201313. https:\/\/doi.org\/10.3109\/08916930109001958.","journal-title":"Autoimmunity"},{"issue":"3","key":"1209_CR31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","volume":"185","author":"L Robles-Carrillo","year":"2010","unstructured":"Robles-Carrillo L, Meyer T, Hatfield M, Desai H, D\u00e1vila M, Langer F, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol. 2010;185(3):1577\u201383. https:\/\/doi.org\/10.4049\/jimmunol.0903888.","journal-title":"J Immunol"},{"issue":"11","key":"1209_CR32","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1111\/j.1600-6143.2008.02382.x","volume":"8","author":"SR Daley","year":"2008","unstructured":"Daley SR, Cobbold SP, Waldmann H. Fc-disabled anti-mouse CD40L antibodies retain efficacy in promoting transplantation tolerance. Am J Transplant. 2008;8(11):2265\u201371. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02382.x.","journal-title":"Am J Transplant"},{"issue":"489","key":"1209_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar6584","volume":"11","author":"JL Karnell","year":"2019","unstructured":"Karnell JL, Albulescu M, Drabic S, et al. A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. Sci Transl Med. 2019;11(489):eaar6584. https:\/\/doi.org\/10.1126\/scitranslmed.aar6584.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1209_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003317","volume":"9","author":"A Kivitz","year":"2023","unstructured":"Kivitz A, Wang L, Alevizos I, et al. The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open. 2023;9(3):e003317. https:\/\/doi.org\/10.1136\/rmdopen-2023-003317.","journal-title":"RMD Open"},{"issue":"6","key":"1209_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/annrheumdis-2018-214729","volume":"78","author":"S Visvanathan","year":"2019","unstructured":"Visvanathan S, Daniluk S, Ptaszy\u0144ski R, et al. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Ann Rheum Dis. 2019;78(6):754\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214729.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1209_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12016-015-8498-3","volume":"50","author":"GwilymJ Webb","year":"2016","unstructured":"Webb Gwilym J, et al. OX40, OX40L and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(3):312\u201332. https:\/\/doi.org\/10.1007\/s12016-015-8498-3.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1209_CR37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jconrel.2021.08.008","volume":"337","author":"Y Fu","year":"2021","unstructured":"Fu Y, Wang L, Liu W, et al. OX40L blockade cellular nanovesicles for autoimmune diseases therapy. J Control Release. 2021;337:557\u201370. https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.008.","journal-title":"J Control Release"},{"issue":"769","key":"1209_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9331","volume":"16","author":"X Rui","year":"2024","unstructured":"Rui X, Alvarez Calderon F, Wobma H, et al. Human OX40L-CAR-T<Subscript>regs<\/Subscript> target activated antigen-presenting cells and control T cell alloreactivity. Sci Transl Med. 2024;16(769):eadj9331. https:\/\/doi.org\/10.1126\/scitranslmed.adj9331.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1209_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-022-00784-6","volume":"18","author":"N Burg","year":"2022","unstructured":"Burg N, Salmon JE, Hla T. Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases. Nat Rev Rheumatol. 2022;18(6):335\u201351. https:\/\/doi.org\/10.1038\/s41584-022-00784-6.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"1209_CR40","doi-asserted-by":"publisher","first-page":"e814","DOI":"10.1016\/S2665-9913(24)00237-6","volume":"6","author":"C Liang","year":"2024","unstructured":"Liang C. Proximod as a potential therapy for rheumatoid arthritis. Lanet Rheumatol. 2024;6(12):e814\u20135. https:\/\/doi.org\/10.1016\/S2665-9913(24)00237-6.","journal-title":"Lanet Rheumatol"},{"key":"1209_CR41","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3389\/fphar.2019.01085","volume":"10","author":"J Jin","year":"2019","unstructured":"Jin J, Ji M, Fu R, et al. Sphingosine-1-phosphate receptor subtype 1 (S1P1) modulator IMMH001 regulates adjuvant- and collagen-induced arthritis. Front Pharmacol. 2019;10:1085.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1209_CR42","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1016\/S2665-9913(24)00199-1","volume":"6","author":"H Zhang","year":"2024","unstructured":"Zhang H, Li Q, Li C, et al. Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial. Lancet Rheumatol. 2024;6(12):e837\u201347. https:\/\/doi.org\/10.1016\/S2665-9913(24)00199-1.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1209_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03337-2","volume":"26","author":"S Cohen","year":"2024","unstructured":"Cohen S, Beebe JS, Chindalore V, et al. A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics\/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Res Ther. 2024;26(1):117. https:\/\/doi.org\/10.1186\/s13075-024-03337-2.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1209_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0500-6","volume":"16","author":"Irene Arroyo-Villa","year":"2014","unstructured":"Arroyo-Villa Irene, et al. Constitutively altered frequencies of circulating follicullar helper T cell counterparts and their subsets in rheumatoid arthritis. Arthritis Res Ther. 2014;16(6):500. https:\/\/doi.org\/10.1186\/s13075-014-0500-6.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1209_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004278","volume":"10","author":"PeterC Taylor","year":"2024","unstructured":"Taylor Peter C, et al. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 2024;10(2):e004278. https:\/\/doi.org\/10.1136\/rmdopen-2024-004278.","journal-title":"RMD Open"},{"key":"1209_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1648290","volume":"16","author":"Wenxian Zhou","year":"2025","unstructured":"Zhou Wenxian, et al. Malondialdehyde-acetaldehyde modified macromolecules and resulting autoantibodies in rheumatoid arthritis pathogenesis: a systematic literature review. Front Immunol. 2025;16:1648290. https:\/\/doi.org\/10.3389\/fimmu.2025.1648290.","journal-title":"Front Immunol"},{"key":"1209_CR47","doi-asserted-by":"crossref","unstructured":"Van Wesemael T, Salioska N, Dorj\u00e9e A, Huizinga T, van der Helm A, Toes R, van der Woude D. Anti-acetylated protein antibodies in rheumatoid arthritis (RA): clues for the starting point of autoantibody responses in RA [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).","DOI":"10.1136\/annrheumdis-2021-eular.2777"},{"issue":"9","key":"1209_CR48","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793\u2013806. https:\/\/doi.org\/10.1002\/art.22025.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1209_CR49","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/imm.13416","volume":"164","author":"C McDonald","year":"2021","unstructured":"McDonald C, Xanthopoulos C, Kostareli E. The role of bruton\u2019s tyrosine kinase in the immune system and disease. Immunology. 2021;164(4):722\u201336. https:\/\/doi.org\/10.1111\/imm.13416.","journal-title":"Immunology"},{"issue":"5","key":"1209_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103532","volume":"23","author":"M De Bondt","year":"2024","unstructured":"De Bondt M, Renders J, Struyf S, Hellings N. Inhibitors of Bruton\u2019s tyrosine kinase as emerging therapeutic strategy in autoimmune diseases. Autoimmun Rev. 2024;23(5):103532. https:\/\/doi.org\/10.1016\/j.autrev.2024.103532.","journal-title":"Autoimmun Rev"},{"key":"1209_CR51","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/art.40059","volume":"69","author":"OBJ Corneth","year":"2017","unstructured":"Corneth OBJ, Verstappen GMP, Paulissen SMJ, De Bruijn MJW, Rip J, Lukkes M, et al. Enhanced bruton\u2019s tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease. Arthritis Rheumatol. 2017;69:1313\u201324. https:\/\/doi.org\/10.1002\/art.40059.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1209_CR52","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2665-9913(23)00089-9","volume":"5","author":"PG Conaghan","year":"2023","unstructured":"Conaghan PG, Nowak M, Du S, et al. Evaluation of BMS-986142, a reversible Bruton\u2019s tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. Lancet Rheumatol. 2023;5(5):e263\u201373. https:\/\/doi.org\/10.1016\/S2665-9913(23)00089-9.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"1209_CR53","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S2665-9913(22)00092-3","volume":"4","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R, Friedman A, Drescher E, et al. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. Lancet Rheumatol. 2022;4(6):e395\u2013406. https:\/\/doi.org\/10.1016\/S2665-9913(22)00092-3.","journal-title":"Lancet Rheumatol"},{"key":"1209_CR54","doi-asserted-by":"publisher","unstructured":"Cohen S, Tuckwell K, Katsumoto TR, et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study). Arthritis Rheumatol. 2020(9). https:\/\/doi.org\/10.1002\/art.41275.","DOI":"10.1002\/art.41275"},{"issue":"1","key":"1209_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14582","volume":"104","author":"S Paliwal","year":"2024","unstructured":"Paliwal S, Bawa S, Shalmali N, Tonk RK. Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis. Chem Biol Drug Des. 2024;104(1):e14582. https:\/\/doi.org\/10.1111\/cbdd.14582.","journal-title":"Chem Biol Drug Des"},{"issue":"17","key":"1209_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179604","volume":"23","author":"Yanis Ramdani","year":"2022","unstructured":"Ramdani Yanis, et al. Monoclonal antibody engineering and design to modulate FcRn activities: a comprehensive review. Int J Mol Sci. 2022;23(17):9604. https:\/\/doi.org\/10.3390\/ijms23179604.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1209_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103016","volume":"21","author":"Emilie Chalayer","year":"2022","unstructured":"Chalayer Emilie, et al. \u201cFc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases.\u201d Autoimmun Rev. 2022;21(3):103016. https:\/\/doi.org\/10.1016\/j.autrev.2021.103016.","journal-title":"Autoimmun Rev"},{"key":"1209_CR58","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","volume":"105","author":"LE Ling","year":"2019","unstructured":"Ling LE, Hillson JL, Tiessen RG, et al. M281, an anti- FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first- in- human study. Clin Pharmacol Ther. 2019;105:1031\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1209_CR59","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41584-025-01259-0","volume":"21","author":"AngelaE Zou","year":"2025","unstructured":"Zou Angela E, et al. \u201cFibroblasts in immune responses, inflammatory diseases and therapeutic implications.\u201d Nat Rev Rheumatol. 2025;21(6):336\u201354. https:\/\/doi.org\/10.1038\/s41584-025-01259-0.","journal-title":"Nat Rev Rheumatol"},{"key":"1209_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102304","volume":"67","author":"Vladislav Tsaltskan","year":"2022","unstructured":"Tsaltskan Vladislav, Firestein Gary S. \u201cTargeting fibroblast-like synoviocytes in rheumatoid arthritis.\u201d Curr Opin Pharmacol. 2022;67:102304. https:\/\/doi.org\/10.1016\/j.coph.2022.102304.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"1209_CR61","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1016\/S2665-9913(21)00061-8","volume":"3","author":"ArthurG Pratt","year":"2021","unstructured":"Pratt Arthur G, et al. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. The Lancet Rheumatology. 2021;3(5):e337\u201346. https:\/\/doi.org\/10.1016\/S2665-9913(21)00061-8.","journal-title":"The Lancet. Rheumatology"},{"issue":"5","key":"1209_CR62","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/13543784.2020.1752660","volume":"29","author":"MD Wiese","year":"2020","unstructured":"Wiese MD, Manning-Bennett AT, Abuhelwa AY. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020;29(5):475\u201382. https:\/\/doi.org\/10.1080\/13543784.2020.1752660.","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"1209_CR63","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/art.41953","volume":"73","author":"A Winkler","year":"2021","unstructured":"Winkler A, Sun W, De S, et al. The interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheumatol. 2021;73(12):2206\u201318. https:\/\/doi.org\/10.1002\/art.41953.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1209_CR64","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024;390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"issue":"2","key":"1209_CR65","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","volume":"80","author":"B Zhang","year":"2021","unstructured":"Zhang B, Wang Y, Yuan Y, et al. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Ann Rheum Dis. 2021;80(2):176\u201384. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217844.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1209_CR66","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","volume":"7","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger M, Nocturne G, Radic M, et al. CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol. 2025;7(6):e434\u201347. https:\/\/doi.org\/10.1016\/S2665-9913(24)00377-1.","journal-title":"Lancet Rheumatol"},{"issue":"6753","key":"1209_CR67","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137. https:\/\/doi.org\/10.1126\/science.ads8473.","journal-title":"Science"},{"issue":"1","key":"1209_CR68","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2321635","volume":"16","author":"Marlena Surowka","year":"2024","unstructured":"Surowka Marlena, Klein Christian. A pivotal decade for bispecific antibodies? mAbs. 2024;16(1):2321635. https:\/\/doi.org\/10.1080\/19420862.2024.2321635.","journal-title":"mAbs"},{"issue":"6","key":"1209_CR69","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"Laura Bucci","year":"2024","unstructured":"Bucci Laura, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024;30(6):1593\u2013601. https:\/\/doi.org\/10.1038\/s41591-024-02964-1.","journal-title":"Nat Med"},{"issue":"10","key":"1209_CR70","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/acr2.11487","volume":"4","author":"Lubna Abuqayyas","year":"2022","unstructured":"Abuqayyas Lubna, et al. Safety and biological activity of Rozibafusp alfa, a bispecific inhibitor of inducible costimulator ligand and B cell activating factor, in patients with rheumatoid arthritis: results of a phase 1b, randomized, double-blind, placebo-controlled, multiple ascending dose study. ACR open rheumatology. 2022;4(10):903\u201311. https:\/\/doi.org\/10.1002\/acr2.11487.","journal-title":"ACR open rheumatology"},{"key":"1209_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369117","volume":"15","author":"Lucille Lamendour","year":"2024","unstructured":"Lamendour Lucille, et al. Bispecific antibodies tethering innate receptors induce human tolerant-dendritic cells and regulatory T cells. Front Immunol. 2024;15:1369117. https:\/\/doi.org\/10.3389\/fimmu.2024.1369117.","journal-title":"Front Immunol"},{"issue":"681","key":"1209_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4419","volume":"15","author":"Nadine Biesemann","year":"2023","unstructured":"Biesemann Nadine, et al. Additive efficacy of a bispecific anti-TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis. Sci Transl Med. 2023;15(681):eabq4419. https:\/\/doi.org\/10.1126\/scitranslmed.abq4419.","journal-title":"Sci Transl Med"},{"key":"1209_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640070","volume":"12","author":"Mathieu Ferrari","year":"2021","unstructured":"Ferrari Mathieu, et al. Novel bispecific antibody for synovial-specific target delivery of anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2021;12:640070. https:\/\/doi.org\/10.3389\/fimmu.2021.640070.","journal-title":"Front Immunol"},{"issue":"1","key":"1209_CR74","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.ard.2025.06.353","volume":"84","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhang X, Zhao C, Zhang R, Zhen J, Pan F, et al. A CD19-TARGETING, CO-STIMULATORY CD28 RECEPTOR-ACTIVATING TRI-SPECIFIC T CELL ENGAGER, FOR THE TREATMENT OF AUTOIMMUNE DISEASES. Ann Rheum Dis. 2025;84(1):1111\u20132. https:\/\/doi.org\/10.1016\/j.ard.2025.06.353.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1209_CR75","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2665-9913(25)00111-0","volume":"7","author":"Fabiola Atzeni","year":"2025","unstructured":"Atzeni Fabiola, Galloway James. Dual JAK and ROCK inhibition and comorbidities in rheumatoid arthritis. The Lancet Rheumatology. 2025;7(9):e595\u20137. https:\/\/doi.org\/10.1016\/S2665-9913(25)00111-0.","journal-title":"The Lancet. Rheumatology"},{"key":"1209_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858069","volume":"13","author":"Angela Rodr\u00edguez-Trillo","year":"2022","unstructured":"Rodr\u00edguez-Trillo Angela, et al. ROCK inhibition with Y-27632 reduces joint inflammation and damage in serum-induced arthritis model and decreases in vitro osteoclastogenesis in patients with early arthritis. Front Immunol. 2022;13:858069. https:\/\/doi.org\/10.3389\/fimmu.2022.858069.","journal-title":"Front Immunol"},{"issue":"9","key":"1209_CR77","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S2665-9913(25)00060-8","volume":"7","author":"Maciej Wieczorek","year":"2025","unstructured":"Wieczorek Maciej, et al. Dual JAK and ROCK inhibition with CPL\u2019116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Rheumatology. 2025;7(9):e629\u201341. https:\/\/doi.org\/10.1016\/S2665-9913(25)00060-8.","journal-title":"The Lancet. Rheumatology"},{"issue":"9","key":"1209_CR78","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.1016\/S2665-9913(20)30172-7","volume":"2","author":"MarkC Genovese","year":"2020","unstructured":"Genovese Mark C, et al. Safety and efficacy of neurostimulation with a miniaturized vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. The Lancet Rheumatology. 2020;2(9):e527\u201338. https:\/\/doi.org\/10.1016\/S2665-9913(20)30172-7.","journal-title":"The Lancet. Rheumatology"},{"issue":"1","key":"1209_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s42234-023-00138-x","volume":"10","author":"Daniel Peterson","year":"2024","unstructured":"Peterson Daniel, et al. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron Med. 2024;10(1):8. https:\/\/doi.org\/10.1186\/s42234-023-00138-x.","journal-title":"Bioelectron Med"},{"key":"1209_CR80","doi-asserted-by":"crossref","unstructured":"Tesser J, June J, Wickersham P, Box J, Valenzuela G, Crowley A, Kumar N, Gaylis N, Lam G, Ridley D, Pinto-Patarroyo G, Chernoff D. Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https:\/\/acrabstracts.org\/abstract\/neuroimmune-modulation-in-adults-with-rheumatoid-arthritis-and-inadequate-response-or-intolerance-to-biological-or-targeted-synthetic-dmards-results-at-12-and-24-weeks-from-a-randomized-sham-control\/. Accessed August 19, 2025.","DOI":"10.1016\/j.ard.2025.05.203"},{"issue":"1","key":"1209_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/10717544.2022.2152136","volume":"30","author":"C Li","year":"2023","unstructured":"Li C, et al. Immunomodulatory nano-preparations for rheumatoid arthritis. Drug Delivery Vol. 2023;30(1):9\u201319. https:\/\/doi.org\/10.1080\/10717544.2022.2152136.","journal-title":"Drug Delivery Vol"},{"key":"1209_CR82","doi-asserted-by":"publisher","DOI":"10.34133\/research.0220","volume":"6","author":"Chenyu Zhang","year":"2023","unstructured":"Zhang Chenyu, et al. Current immunotherapy strategies for rheumatoid arthritis: the immunoengineering and delivery systems. Research. 2023;6:0220. https:\/\/doi.org\/10.34133\/research.0220.","journal-title":"Research"},{"key":"1209_CR83","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jconrel.2022.08.020","volume":"350","author":"Nan Zhang","year":"2022","unstructured":"Zhang Nan, et al. From vaccines to nanovaccines: a promising strategy to revolutionize rheumatoid arthritis treatment. J Control Release. 2022;350:107\u201321. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.020.","journal-title":"J Control Release"}],"updated-by":[{"DOI":"10.1007\/s11926-026-01215-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000}}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01209-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-025-01209-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01209-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:01:57Z","timestamp":1773781317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-025-01209-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1007\/s11926-025-01209-5","relation":{},"ISSN":["1534-6307"],"issn-type":[{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to include the following text: 'Figure created with BioRender.com' in the captions for Figures 1, 2, and 3.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11926-026-01215-1","URL":"https:\/\/doi.org\/10.1007\/s11926-026-01215-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Moreland reports recent or current consulting or clinical trial site investigator for the following companies: Boehringer Ingelheim International GmbHCelltrion, IncMerck Sharpe and DohmeNeurocrine BioscienceGaldermaLegend BiotechSonoma BiotherapeuticsNovartisAmgenIgM BiosciencesAllogene TherapeuticsBristol Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}